Dragonfly Therapeutics
26 articles about Dragonfly Therapeutics
-
Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting
6/2/2023
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced an oral presentation of Phase 1 DF1001 Monotherapy Dose Escalation Results scheduled on Sunday June 4, from 11:45 - 11:57 a.m.
-
Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team to help Manage its Growing Clinical Pipeline
6/1/2023
Dragonfly Therapeutics, Inc., announced it has expanded its clinical leadership team with the addition of Dr. Robin Edwards, previously Global Head of Translational Sciences at Daiichi Sankyo and Head of Translational at Bristol Myers Squibb, and Dr. David Ferry, previously Head of GI Oncology at Eli Lilly.
-
Dragonfly Therapeutics Announces the Publication of Preclinical Data Supporting DF6002, its Extended Half-life IL-12 Cytokine, as A Promising Treatment for Cancer
4/17/2023
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced the April 13th publication of preclinical data in Cell Press's Med supporting DF6002 as a promising treatment option for cancer patients.
-
Bristol Myers Squibb has returned the rights for interleukin-12 immunotherapy program DF6002 back to its original owner, Dragonfly Therapeutics, the companies announced Monday.
-
Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program
2/6/2023
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced it now owns all rights to develop DF6002, its novel interleukin-12 (IL-12) cytokine investigational immunotherapy program, which is in Phase 1 clinical development, with dose escalation progressing successfully in monotherapy and in combination with nivolumab, in the U.S. and in Europe.
-
Dr. Joseph E. Eid, Who Led Merck's Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D
2/1/2023
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that Joseph E. Eid, M.D., has joined the Company as President of Research and Development.
-
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
1/6/2023
Dragonfly Therapeutics, Inc. today announced that Bristol Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, that will bring the total drug candidates licensed by Bristol Myers Squibb to seven including Dragonfly's novel IL12 cytokine DF6002/BMS-986415.
-
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET®
12/8/2022
Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2.
-
Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET® DF1001 in Patients with Advanced Solid Tumors
12/6/2022
Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001.
-
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
11/21/2022
Nona Biosciences announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona's proprietary fully human heavy chain only antibody transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
-
Dragonfly Therapeutics Announces First Patient Dosed in Clinical Trial Evaluating Solid Tumor Targeting TriNKET® Conducted by Merck
11/1/2022
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid tumor targeting TriNKET developed by Dragonfly.
-
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
5/2/2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications.
-
Gilead and Dragonfly announced their collaboration today, with an end goal of bringing the DF7001 NK engager program designed for patients with cancer or inflammatory diseases.
-
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
4/20/2022
Dragonfly Therapeutics, Inc. today announced an expansion of its research collaboration with AbbVie (NYSE: ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases.
-
Dragonfly Therapeutics Expands Clinical Leadership Team, Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs
3/30/2022
Dragonfly Therapeutics, Inc., announced it has expanded its Clinical Leadership Team with the addition of Dr. Hesham Aboshady, an experienced clinician as Head of Drug Safety, and Rajesh Israni as Head of Regulatory.
-
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
3/1/2022
Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the achievement of a Phase 1 clinical development milestone for the DF6002/BMS-9896415 IL-12 program.
-
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
-
Dragonfly Therapeutics Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer
11/9/2021
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that its wholly-owned HER2-targeted NK cell engager therapy, DF1001, has been granted Orphan Drug Designation (ODD) in the US for treatment of esophageal cancer.
-
Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors
12/1/2020
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Canada , has licensed its first TriNKET™ immunotherapy candidate from Dragonf
-
Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program.